Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2001

View Archived Issues

Aurora and R.W. Johnson expand ion channel technology agreement

Warning issued regarding Zerit/Videx combination therapy use in pregnant women

Cambridge NeuroScience receives SBIR grant related to peripheral nerve dysfunction

European commercialization license for Cidecin granted to Gilead

Cell Therapeutics outlines 2001 goals

Anticocaine catalytic MAb selectively attenuates cocaine selfadministration in rats

Neurogen and Pfizer extend collaboration related to GABA system

Coronary artery stenosis prevented by TAS-301 in pigs with balloon overstretch injury

BioChem Pharma completes acquisition of CliniChem

Efficacy and safety of JAK3 inhibitors in allergic asthma validated using WHI-P97

Oxford BioMedica develops Lentivector transport technology with neurological applications

FDA issues nonapprovable letter for Atragen; company plans to continue development

Four-year PROactive study examines effects of Actos on cardiovascular risk

Wide series of CDK/cyclin inhibitors developed at Pharmacia

Symbicort combination asthma product approved in E.U.

Short-acting benzodiazepines and their use claimed by Glaxo (GlaxoSmithKline)

Inhibitors of essential bacterial enzymes disclosed in recent patent

Benzimidazole-based antibacterial agents in the GlaxoSmithKline pipeline

New substance P antagonists particularly useful for emesis

Several related classes of anticoagulants, their preparation, activity and use reported

Matrix completes NDA filing for IntraDose injectable gel

Important Japanese approvals received and pending for AstraZeneca

Zometa granted positive opinion from CPMP

IND submitted for salmon calcitonin as oral osteoporosis treatment

Phytopharm reports promising clinical trial results for P-54 in colorectal cancer

Potent new nonpeptide ORL1 receptor agonist discovered at Novo Nordisk

Novogen begins second phase I trial of anticancer agent in Australia

Ferring designs very-long-acting GnRH antagonist with other advantageous properties

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...